Research map: Clinical harm from failure to deploy personalized medicine for patients with metastatic non–small cell lung cancer

Back to the article

Papers in this map

  1. Cancer statistics, 2025 · Rebecca L. Siegel · 2025 · 2992 citations · Cited by this paper
  2. Health care cost trajectories among patients with cancer and cardiometabolic comorbidities over a decade including the pandemic period · 2026 · Related
  3. Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non–Small Cell Lung Cancer Using a Clinicogenomic Database · Gaurav Singal · 2019 · 576 citations · Cited by this paper
  4. Principles and practices for successful gene therapy innovative contracting: Insights from a multistakeholder convening · 2026 · Related
  5. Update 2025: Management of Non‑Small-Cell Lung Cancer · Hyein Jeon · 2025 · 184 citations · Cited by this paper
  6. Timing of health technology assessment in the United States: An evaluation of ICER reviews over 8 years · 2026 · Related
  7. Impact of Clinical Practice Gaps on the Implementation of Personalized Medicine in Advanced Non–Small-Cell Lung Cancer · Helen Sadik · 2022 · 119 citations · Cited by this paper
  8. Incremental health care resource utilization, costs, and predictors of high costs in generalized myasthenia gravis · 2026 · Related
  9. Disparities in Receiving Guideline-Concordant Treatment for Lung Cancer in the United States · Erik F. Blom · 2019 · 116 citations · Cited by this paper
  10. Cost-effectiveness analysis of treatment strategies initiating with second-generation antipsychotic long-acting injectables in patients with schizophrenia in the United States · 2026 · Related
  11. Compromised Outcomes in Stage IV Non–Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World Data · Jeffrey Alan Scott · 2023 · 60 citations · Cited by this paper
  12. Incidence of amyloid-related imaging abnormalities and health resource utilization in patients with Alzheimer disease receiving monoclonal antibody treatments: A real-world evidence study · 2026 · Related
  13. Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer · Charu Aggarwal · 2023 · 49 citations · Cited by this paper
  14. Patient experience data in formulary decision-making: Payer-reported perceptions and use · 2026 · Related
  15. Cost-Effectiveness of Parallel Versus Sequential Testing of Genetic Aberrations for Stage IV Non–Small-Cell Lung Cancer in the Netherlands · Henri B. Wolff · 2022 · 39 citations · Cited by this paper
  16. Evaluating the design and implementation challenges of the Centers for Medicare & Medicaid Services’ Cell and Gene Therapy Access Model · 2026 · Related
  17. Next-Generation Sequencing: A Review of Its Transformative Impact on Cancer Diagnosis, Treatment, and Resistance Management · Alexandru Isaic · 2025 · 38 citations · Cited by this paper
  18. Do Targeted NGS Panels Include NSCLC Guideline-Recommended Biomarkers? · 2026 · Related
  19. Strategies to Address the Clinical Practice Gaps Affecting the Implementation of Personalized Medicine in Cancer Care · Apostolia Maria Tsimberidou · 2024 · 35 citations · Cited by this paper
  20. Diagnostic Validation of a Comprehensive Targeted Panel for Broad Mutational and Biomarker Analysis in Solid Tumors · Guy Froyen · 2022 · 34 citations · Cited by this paper
  21. Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer · James Signorovitch · 2018 · 31 citations · Cited by this paper
  22. Emerging molecular testing paradigms in non-small cell lung cancer management—current perspectives and recommendations · Frederique Madeleine Penault-Llorca · 2024 · 25 citations · Cited by this paper
  23. Next Generation Sequencing of Advanced Non–Small Cell Lung Cancer: Utilization Based on Race and Impact on Survival · Asrar A. Alahmadi · 2020 · 24 citations · Cited by this paper
  24. Trends in Real-World Biomarker Testing and Overall Survival in US Patients with Advanced Non-Small-Cell Lung Cancer · Ning Wu · 2022 · 22 citations · Cited by this paper
  25. Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator · Albrecht Stenzinger · 2023 · 22 citations · Cited by this paper
  26. Real-World Biomarker Testing Patterns in Patients With Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) in a US Community-Based Oncology Practice Setting · Anthony N. Sireci · 2023 · 21 citations · Cited by this paper
  27. Biomarker Testing, Treatment, and Outcomes in Patients With Advanced/Metastatic Non–Small Cell Lung Cancer Using a Real-World Database · Naleen Raj Bhandari · 2023 · 21 citations · Cited by this paper
  28. Validating a targeted next-generation sequencing assay and profiling somatic variants in Chinese non-small cell lung cancer patients · Ruirui Jiang · 2020 · 18 citations · Cited by this paper
  29. Budget Impact Analysis of Comprehensive Genomic Profiling in Patients With Advanced Non–Small-Cell Lung Cancer · Michael J. Harvey · 2021 · 18 citations · Cited by this paper
  30. Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancer · Christine M. Bestvina · 2024 · 14 citations · Cited by this paper
  31. The American Cancer Society National Lung Cancer Roundtable strategic plan: Advancing comprehensive biomarker testing in non–small cell lung cancer · Adam H. Fox · 2024 · 13 citations · Cited by this paper
  32. Access to Tyrosine Kinase Inhibitors and Survival in Patients with Advanced EGFR+ and ALK+ Positive Non–small-cell Lung Cancer Treated in the Real-World · Bernardo H. L. Goulart · 2021 · 12 citations · Cited by this paper
  33. Racial and ethnic disparities in genomic testing among lung cancer patients: a systematic review · Clare Meernik · 2024 · 12 citations · Cited by this paper
  34. Real-World Analysis of Disparities in Biomarker Testing and Use of Recommended Targeted Therapies in Metastatic Non–Small Cell Lung Cancer in the United States · Michael J. Dennis · 2025 · 11 citations · Cited by this paper
  35. Cost-Effectiveness Analysis of Comprehensive Genomic Profiling in Patients with Advanced Non–Small-Cell Lung Cancer Using Real-World Data · Scott Spencer · 2025 · 11 citations · Cited by this paper
  36. Relative Impact of Anticancer Therapy on Unplanned Hospital Care in Patients With Non–Small-Cell Lung Cancer · Manan P. Shah · 2020 · 10 citations · Cited by this paper
  37. Contemporary biomarker testing rates in both early and advanced NSCLC: Results from the MYLUNG pragmatic study. · Makenzi Colleen Evangelist · 2023 · 10 citations · Cited by this paper
  38. Costs of biomarker testing in advanced non‐small cell lung cancer: a global study comparing next‐generation sequencing and single‐gene testing · Umberto Malapelle · 2025 · 10 citations · Cited by this paper
  39. Closing the Testing Gap: Standardization of Comprehensive Biomarker Testing for Metastatic Non–Small-Cell Lung Cancer in a Large Community Oncology Practice · David Michael Waterhouse · 2023 · 9 citations · Cited by this paper

Source: OpenAlex (CC0)